A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical company Regeneron, located in Tarrytown, New York. The trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The immune system actually wants to fight SARS-CoV-2 with antiviral signaling molecules. But a research team from Charité and MDC has now shown how such a signaling molecule can promote the replication of the virus. The results have been published in the journal "EMBO Molecular Medicine".
When it comes to understanding the transfer of coronavirus, important new studies have determined that there is a significant difference between COVID-19 positive people who have symptoms, including fever, and COVID positive people who do not.
A clinical study led by Dr. Jordan Feld, a liver specialist at Toronto Centre for Liver Disease, University Health Network (UHN), showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized.
An international team of researchers led by the Universities of Liverpool and Keele, working with Public Health England, has found that the common anticoagulant drug heparin inhibits the SARS-Cov2 virus spike protein, by reducing the virus’ ability to attach to human cells and infect them.
Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.
In a US study published in Science, researchers detected immune memory to SARS-CoV-2 across all immune cell types studied for as long as 8 months after patients became ill with COVID-19.
The study was carried out with data from 89 patients admitted to the IFEMA Hospital The data show that telomeres are shorter in patients suffering more severe COVID-19 pathologies The researchers propose that one of the consequences of the viral infection is shortening of the telomeres, which, in turn, hampers the regeneration of lung tissue and causes prolonged sequelae in some patients The study, published in the journal Aging, suggests the usefulness of a possible therapy for patients with post-COVID pulmonary injury based on activation of the enzyme telomerase